Published April 11, 2024
| Version v1
Journal article
Open
A protective role for type I interferon signaling following infection with Mycobacterium tuberculosis carrying the rifampicin drug resistance-conferring RpoB mutation H445Y
Creators
- 1. Washington University in St. Louis
- 2. University of Chicago
- 3. Columbia University
Description
Interleukin-1 (IL-1) signaling is essential for controlling virulent Mycobacterium tuberculosis (Mtb) infection since antagonism of this pathway leads to exacerbated pathology and increased susceptibility. In contrast, the triggering of type I interferon (IFN) signaling is associated with the progression of tuberculosis (TB) disease and linked with negative regulation of IL-1 signaling. However, mice lacking IL-1 signaling can control Mtb infection if infected with an Mtb strain carrying the rifampin-resistance conferring mutation H445Y in its RNA polymerase β subunit (rpoB-H445Y Mtb). The mechanisms that govern protection in the absence of IL-1 signaling during rpoB-H445Y Mtb infection are unknown. In this study, we show that in the absence of IL-1 signaling, type I IFN signaling controls rpoB-H445Y Mtb replication, lung pathology, and excessive myeloid cell infiltration. Additionally, type I IFN is produced predominantly by monocytes and recruited macrophages and acts on LysM-expressing cells to drive protection through nitric oxide (NO) production to restrict intracellular rpoB-H445Y Mtb. These findings reveal an unexpected protective role for type I IFN signaling in compensating for deficiencies in IL-1 pathways during rpoB-H445Y Mtb infection.
Data availability
All data that support the findings of this study are within the manuscript and its Supporting Information. Sequencing data that support the findings of this study have been deposited in GEO and are publicly available (GSE249400 and GSE249401).
Files
journal.ppat.1012137.pdf
Files
(8.5 MB)
| Name | Size | Download all |
|---|---|---|
|
Supporting information md5:759f2c6ccd0f78df72dd8be6d46c87fa |
6.6 MB | Preview Download |
|
Article md5:e1c5f330ce49ec6ef10de523b97b7496 |
1.9 MB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1371/journal.ppat.1012137
- Other
- oai:uchicago.tind.io:11575
Funding
- National Institutes of Health
- 5R01 HL105427
- National Institutes of Health
- 2R01AI111914-06A1
- National Institutes of Health
- 5R01AI134236-04
- National Institutes of Health
- 5R01AI123780-03
- National Heart, Lung, and Blood Institute
- T32 HL007317-44
- National Institute of Allergy and Infectious Diseases
- 2R01AI130454